RxDoctor Payments Data

Sarah Johns, PA

Medical · Springfield, VANPI 1700029295

Payments from drug & device makers

$5,034in general payments, 2019–2025

Across 242 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$999
  • AstraZeneca$639
  • Pfizer$355
  • Amgen$346
  • Astellas Pharma US Inc$295
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$5,034100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,034 in reported general payments places this provider in the 85th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$56,346
Medicare patients
166
Services billed
1,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$42,551
OzempicSemaglutide16$31,553
SynthroidLevothyroxine Sodium27$2,722
Albuterol Sulfate HfaAlbuterol Sulfate42$1,142
Atorvastatin Calcium122$1,016
Pantoprazole Sodium50$883
Rosuvastatin Calcium57$856
Esomeprazole Magnesium12$756
Phenobarbital11$706
Levothyroxine Sodium94$702
Olmesartan Medoxomil27$694
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$622
Escitalopram Oxalate45$617
Losartan Potassium56$591
Metoprolol Succinate31$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$179$42,55128 claims
Novo NordiskOzempic$999$31,55316 claims
AbbVieSynthroid$1,066$2,72227 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$70294 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 632 medical providers in Virginia.

Other medical in Springfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →